I don't mind the idea of a JV to be honest. Neuren doing the preclinical and up to phase 2/3 and their partner responsible for approval, marketing and distribution.
Neuren has a supermarket of indications, why not have each party do what they do best. They can work out an agreed contribution/distribution percentage for each indication they try to commercialise.
Getting traction in US surely would need a US based entity to increase chances and negotiations with FDA. Especially if "America First" is a strong theme for the next 4 years. If it is Acadia, at least it is all in-house and they can just get on with it as their partnership has been excellent to date.
Not opposed to a takeover at the right price of course, but not at bargain basement rates.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)